RAPT Therapeutics Inc (RAPT)
4.03
-0.11
(-2.66%)
USD |
NASDAQ |
May 17, 16:00
4.03
0.00 (0.00%)
After-Hours: 20:00
RAPT Therapeutics Cash from Financing (Quarterly): 9.036M for March 31, 2024
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 9.036M |
| December 31, 2023 | 0.458M |
| September 30, 2023 | 0.106M |
| June 30, 2023 | 0.767M |
| March 31, 2023 | 0.116M |
| December 31, 2022 | 75.36M |
| September 30, 2022 | 5.251M |
| June 30, 2022 | 50.44M |
| March 31, 2022 | 0.132M |
| December 31, 2021 | 0.601M |
| September 30, 2021 | 0.472M |
| June 30, 2021 | 139.11M |
| March 31, 2021 | 1.301M |
| Date | Value |
|---|---|
| December 31, 2020 | 4.56M |
| September 30, 2020 | 0.165M |
| June 30, 2020 | 0.864M |
| March 31, 2020 | 69.87M |
| December 31, 2019 | 34.74M |
| September 30, 2019 | 0.663M |
| June 30, 2019 | 7.485M |
| March 31, 2019 | 7.013M |
| December 31, 2018 | 22.62M |
| September 30, 2018 | 0.062M |
| June 30, 2018 | 29.96M |
| March 31, 2018 | 0.087M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
0.106M
Minimum
Sep 2023
139.11M
Maximum
Jun 2021
20.07M
Average
1.082M
Median
Cash from Financing (Quarterly) Benchmarks
| Emergent BioSolutions Inc | 40.70M |
| Avinger Inc | -0.061M |
| Tonix Pharmaceuticals Holding Corp | -0.212M |
| Skye Bioscience Inc | 85.65M |
| Axsome Therapeutics Inc | -1.187M |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -27.08M |
| Cash from Investing (Quarterly) | 15.89M |
| Free Cash Flow | -106.00M |
| Free Cash Flow Per Share (Quarterly) | -0.7039 |
| Free Cash Flow Yield | -68.28% |